Navigation Links
AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
Date:12/3/2008

WILMINGTON, Del., Dec. 3 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the appointment of Graham Baker as Vice President and Chief Financial Officer of AstraZeneca North America.

Graham will be responsible for all Finance and Information Services matters in North America, effective January 1, 2009. He will be a member of the US Leadership Team and will report to Rich Fante, President, AstraZeneca US.

In announcing Baker's appointment, Fante said, "Graham brings a wealth of expertise and experience that will be central as we deliver continued business success and make a meaningful difference to patient health."

Graham has 18 years of finance experience, including 13 at AstraZeneca, most recently as Regional Finance Director, Asia Pacific, based in Singapore. In this role, he was accountable for Finance, Information Services and Sourcing across the Asia Pacific Region and the delivery of sales, costs and profits in this key growth region for the company. As a member of the regional management team, Graham was also closely involved with all major investments across 13 countries, including significant expansions in China, India and Indonesia.

Before that, Graham held several finance leadership positions, including CFO of AstraZeneca Japan, Business Development Director responsible for financial and commercial evaluations of key acquisitions, and Global Marketing Finance Director for the cardiovascular therapy area. Prior to joining AstraZeneca, he qualified as a Chartered Accountant and Chartered Tax Advisor working for Arthur Andersen. Graham holds an MA degree in Economics from Cambridge University in England.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information visit www.astrazeneca-us.com.


'/>"/>
SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
2. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
3. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
4. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
5. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
6. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
8. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
9. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
10. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
11. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... -- Aratana Therapeutics, Inc. (NASDAQ: PETX ), ... and commercialization of innovative biopharmaceutical products for companion animals, ... North America 2016. ... the FDA approval of three innovative therapeutics in 2016, ... oral solution) and NOCITA ® (bupivacaine liposome injectable ...
(Date:1/20/2017)... http://www.Financialbuzz.com - According ... causes of death worldwide. There were 8.2 million cancer ... related deaths increased gradually over time, the death rates ... various cancers continues to drive demand of biological therapies ... Market Insights, Inc. cancer biological therapy market size was USD ...
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
Breaking Biology Technology:
(Date:1/12/2017)... research undertaken by Fit Small Business has revealed ... simply asked which office technology had they not used in ... Insights on what will be key features in ... industry leaders including Penelope Trunk , Martin Lindstrom ... Some of these findings included; ...
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
Breaking Biology News(10 mins):